ACADIA Pharmaceuticals Inc.
ACAD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $957,797 | $726,437 | $517,235 | $484,145 |
| % Growth | 31.8% | 40.4% | 6.8% | – |
| Cost of Goods Sold | $81,841 | $45,731 | $10,166 | $19,141 |
| Gross Profit | $875,956 | $680,706 | $507,069 | $465,004 |
| % Margin | 91.5% | 93.7% | 98% | 96% |
| R&D Expenses | $303,249 | $351,619 | $361,575 | $239,415 |
| G&A Expenses | $0 | $393,066 | $0 | $396,028 |
| SG&A Expenses | $488,428 | $402,466 | $369,090 | $396,028 |
| Sales & Mktg Exp. | $0 | $9,400 | $0 | $0 |
| Other Operating Expenses | -$146,515 | $0 | $0 | $0 |
| Operating Expenses | $645,162 | $754,085 | $730,665 | $635,443 |
| Operating Income | $230,794 | -$73,379 | -$223,596 | -$170,439 |
| % Margin | 24.1% | -10.1% | -43.2% | -35.2% |
| Other Income/Exp. Net | $27,281 | $22,343 | $10,152 | $2,920 |
| Pre-Tax Income | $258,075 | -$51,036 | -$213,444 | -$167,519 |
| Tax Expense | $31,624 | $10,250 | $2,531 | $351 |
| Net Income | $226,451 | -$61,286 | -$215,975 | -$167,870 |
| % Margin | 23.6% | -8.4% | -41.8% | -34.7% |
| EPS | 1.37 | -0.37 | -1.34 | -1.05 |
| % Growth | 470.3% | 72.4% | -27.6% | – |
| EPS Diluted | 1.36 | -0.37 | -1.34 | -1.05 |
| Weighted Avg Shares Out | 165,717 | 163,819 | 161,683 | 160,493 |
| Weighted Avg Shares Out Dil | 166,362 | 163,819 | 161,683 | 160,493 |
| Supplemental Information | – | – | – | – |
| Interest Income | $25,458 | $17,234 | $6,610 | $591 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $15,883 | $5,552 | $2,026 | $3,344 |
| EBITDA | $100,162 | -$67,827 | -$221,570 | -$167,095 |
| % Margin | 10.5% | -9.3% | -42.8% | -34.5% |